Form 4: Jazz Pharmaceuticals CEO Sells Shares Under 10b5-1 Plan

Jazz Pharmaceuticals CEO Bruce C. Cozadd sold 2,000 ordinary shares on December 2, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Bruce C. Cozadd, the Chairman and CEO of Jazz Pharmaceuticals, sold 2,000 ordinary shares on December 2, 2024.
• The sale was executed at a price of $121.17 per share.
• This transaction was conducted under a pre-established Rule 10b5-1 trading plan.
• Additionally, Mr. Cozadd acquired 49 ordinary shares on November 29, 2024, through the company's Employee Stock Purchase Plan.
• Following these transactions, Mr. Cozadd directly owns 427,025 ordinary shares.

Sentiment

Score: 5

Explanation: The document reflects a routine insider transaction under a pre-arranged plan, which is neither particularly positive nor negative. It's a neutral event.

Risks

• Sales by company insiders, even under pre-arranged plans, can sometimes be perceived negatively by the market.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and these transactions are closely monitored by investors and regulators. The use of 10b5-1 plans is a common practice to avoid accusations of trading on inside information.

Comparison to Industry Standards

• Sales by executives under 10b5-1 plans are a standard practice across the pharmaceutical industry, with companies like AbbVie, Amgen, and Gilead Sciences also seeing similar filings.
• The volume of shares sold by Mr. Cozadd is relatively small compared to the total outstanding shares of Jazz Pharmaceuticals, which is typical for routine insider sales.

Stakeholder Impact

• The sale of shares by the CEO may have a minor impact on shareholder sentiment, but it is unlikely to cause significant concern given the pre-arranged nature of the transaction.

Key Dates

Keywords

insider trading, Form 4, stock sale, Rule 10b5-1, Jazz Pharmaceuticals, Bruce C. Cozadd, executive compensation, stock ownership